Hattori, Sachiko
Clinical trials referenced in this document:
Documents that mention this clinical trial
Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes
https://doi.org/10.1186/s13098-020-00533-3
Article History
Received: 29 November 2019
Accepted: 15 March 2020
First Online: 24 March 2020
Ethics approval and consent to participate
: The Ethics Committee at Tohto Clinic approved this study, and all participating patients provided written informed consent before starting the study.
: Not applicable.
: The author has no competing interests to declare.